AZN

Astrazeneca plc ADR

Oct 21 • 11:11AM ET

83.50

-0.37 -0.45 %

Healthcare • Drug Manufacturers - General • United Kingdom • NASD

Peers: ABBV PFE JNJ MRK NVS BMY GSK SNY LLY AMGN

| Held by: QQQ QQQM PVAL CGGO PPH DIHP DFIC AVDE FVD TQQQ

Index	NDX	P/E	31.32	EPS (ttm)	2.67	Insider Own	0.01%	Shs Outstand	3.10B	Perf Week	-1.91%
Market Cap	258.88B	Forward P/E	16.18	EPS next Y	5.16	Insider Trans	0.00%	Shs Float	3.10B	Perf Month	7.74%
Enterprise Value	284.70B	PEG	2.63	EPS next Q	1.14	Inst Own	16.27%	Short Float	0.18%	Perf Quarter	14.38%
Income	8.32B	P/S	4.57	EPS this Y	11.33%	Inst Trans	-3.60%	Short Ratio	1.08	Perf Half Y	23.02%
Sales	56.59B	P/B	5.79	EPS next Y	12.92%	ROA	7.68%	Short Interest	5.46M	Perf YTD	27.44%
Book/sh	14.42	P/C	36.42	EPS next 5Y	11.91%	ROE	19.76%	52W High	86.57 -3.55%	Perf Year	7.02%
Cash/sh	2.29	P/FCF	22.52	EPS past 3/5Y	285.92% 34.53%	ROIC	11.77%	52W Low	61.24 36.34%	Perf 3Y	51.89%
Dividend Est.	1.62 (1.94%)	EV/EBITDA	15.16	Sales past 3/5Y	12.66% 17.18%	Gross Margin	72.56%	Volatility	1.56% 1.81%	Perf 5Y	56.98%
Dividend TTM	1.56 (1.87%)	EV/Sales	5.03	EPS Y/Y TTM	29.15%	Oper. Margin	21.13%	ATR (14)	1.52	Perf 10Y	166.76%
Dividend Ex-Date	Aug 08, 2025	Quick Ratio	0.67	Sales Y/Y TTM	15.08%	Profit Margin	14.71%	RSI (14)	56.09	Recom	1.61
Dividend Gr. 3/5Y	2.54% 2.10%	Current Ratio	0.86	EPS Q/Q	28.74%	SMA20	1.61%	Beta	0.34	Target Price	94.55
Payout	66.95%	Debt/Eq	0.73	Sales Q/Q	13.06%	SMA50	3.73%	Rel Volume	1.07	Prev Close	83.87
Employees	94300	LT Debt/Eq	0.58	Earnings	Nov 06 BMO	SMA200	13.35%	Avg Volume	5.05M	Price	83.50
IPO	May 12, 1993	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.44% 2.55%	Trades		Volume	1,593,225	Change	-0.45%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-16-25	Downgrade	Deutsche Bank	Hold → Sell
Apr-15-25	Initiated	Exane BNP Paribas	Outperform	$75
Feb-13-25	Upgrade	UBS	Neutral → Buy
Feb-12-25	Initiated	Morgan Stanley	Overweight
Nov-20-24	Upgrade	UBS	Sell → Neutral
Nov-06-24	Upgrade	Deutsche Bank	Sell → Hold
Sep-13-24	Downgrade	Deutsche Bank	Hold → Sell
May-30-24	Initiated	Goldman	Buy	$97
Apr-16-24	Upgrade	Deutsche Bank	Sell → Hold
Feb-08-24	Downgrade	Deutsche Bank	Hold → Sell
Jan-23-24	Initiated	Morgan Stanley	Overweight	$85
Jan-16-24	Resumed	UBS	Sell
Jan-03-24	Downgrade	Jefferies	Buy → Hold	$78.50 → $70
Dec-18-23	Initiated	HSBC Securities	Buy	$78
Sep-25-23	Upgrade	Jefferies	Hold → Buy	$66.50 → $80
Jul-14-23	Initiated	HSBC Securities	Buy
Jul-12-23	Upgrade	UBS	Neutral → Buy
Jul-05-23	Downgrade	Deutsche Bank	Buy → Hold
Apr-11-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-05-23	Initiated	BMO Capital Markets	Outperform	$82

Show Previous Ratings

Today 10:39AM	Did IonQ Just Unlock Quantum Computings True Potential And a Massive Stock Rally? (24/7 Wall St.)
06:51AM	The Zacks Analyst Blog Highlights AstraZeneca, RTX, Applied Materials, Park Aerospace and NetSol Technologies (Zacks)
Oct-20-25 04:28PM	Top Research Reports for AstraZeneca, RTX & Applied Materials (Zacks)
03:45PM	AstraZeneca's Cancer Breakthrough: Enhertu Data Sparks New Hope for Early Breast Cancer Cure (GuruFocus.com)
10:10AM	Here's What to Expect From AbbVie's Oncology Segment in Q3 Earnings (Zacks)
09:50AM	Loading…
09:50AM	Here's Why Astrazeneca (AZN) is a Strong Momentum Stock (Zacks)
06:53AM	AstraZeneca hails major breakthroughs with breast-cancer drugs (MarketWatch)
Oct-19-25 07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option (Business Wire)
Oct-18-25 10:35AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial (Business Wire)
10:30AM	AstraZeneca, In A Buy Zone, Makes A Big Breast Cancer Splash (Investor's Business Daily)
10:30AM	ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial (Business Wire)
10:30AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial (Business Wire)
Oct-17-25 06:15PM	Astrazeneca (AZN) Outpaces Stock Market Gains: What You Should Know (Zacks)
04:17PM	TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps (Business Wire)
12:20PM	Will Declining Gardasil Sales Ail MRK's Top Line in Q3 Earnings? (Zacks)
12:11PM	Loading…
12:11PM	Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings? (Zacks)
08:10AM	IMFINZI (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial (Business Wire)
08:00AM	IMFINZI (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial (Business Wire)
Oct-16-25 01:55PM	LLY's Oral GLP-1 Pill Scores Another Pair of Diabetes Wins (Zacks)
09:48AM	2 Pharmaceutical Growth Stocks to Buy Now and Hold for Decades (Motley Fool)
07:23AM	AstraZeneca cut to Sell by Deutsche Bank on pipeline doubts, patent risk (Investing.com)
Oct-15-25 01:19PM	Trump Locks In AstraZeneca Deal to Slash Medicaid Drug Prices -- Big Pharma Faces New Reality (GuruFocus.com)
10:00AM	AstraZeneca unveils expanded manufacturing facility in Texas (Business Wire)
09:20AM	Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX? (Zacks)
Oct-14-25 09:45AM	Astrazeneca (AZN) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
08:43AM	Johnson & Johnson Earnings Beat Estimates. Why the Stock Is Dropping. (Barrons.com)
06:20AM	Johnson & Johnson Says It Will Spin Off Orthopaedics Business (Barrons.com)
Oct-13-25 03:24PM	Trumps AstraZeneca Deal Echoes Pfizer Pact. Big Pharmas Political Headaches Are Easing. (Barrons.com)
01:40PM	AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve (Zacks)
09:59AM	US-China Trade Tension Escalates: Should You Seek Refuge in UK ETFs? (Zacks)
09:40AM	Loading…
09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
07:54AM	Stocks to Watch Monday: Fastenal, Tesla, JPMorgan, Warner Bros. (The Wall Street Journal)
07:00AM	AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO (Business Wire)
05:33AM	Stocks to Watch Monday: AMD, Nvidia, Warner Bros, Alibaba (The Wall Street Journal)
03:45AM	Company News for Oct 13, 2025 (Zacks)
Oct-12-25 06:50PM	Analyst Report: AstraZeneca PLC (Morningstar Research)
Oct-10-25 08:27PM	AstraZeneca Cuts Discounted Drug Pricing Deal With the White House. The Stock Is Rising. (Barrons.com)
07:11PM	AstraZeneca Strikes Drug-Pricing Deal With Trump Administration (The Wall Street Journal)
06:39PM	Trump reaches deal with AstraZeneca to lower U.S. drug prices (CNBC TV)
06:39PM	Pres. Trump announces deal with AstraZeneca to lower U.S. drug prices (CNBC TV)
04:38PM	AstraZeneca to Ink Drug-Pricing Deal With Trump Administration (The Wall Street Journal)
03:45PM	AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market. (MarketWatch)
11:57AM	Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? (Zacks)
Oct-09-25 12:30PM	AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs (Business Wire)
09:52AM	BDTX Stock Hits 52 Week High: Is There More Room for Growth? (Zacks)
06:00AM	Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery (PR Newswire)
Oct-08-25 11:15AM	AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study (Zacks)
08:50AM	Here's What to Expect From Pfizer's Oncology Drugs in Q3 Earnings (Zacks)
Oct-07-25 09:43AM	Best Stocks To Watch: Two New IPOs, Pharma Titan AstraZeneca And Electrical Grid Play Emcor Trade Near Buy Points (Investor's Business Daily)
08:39AM	Thermo Fisher's New R&D Alliance With AstraZeneca May Lift Its Stock (Zacks)
07:00AM	Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension (Business Wire)
Oct-06-25 01:57PM	Eli Lilly Stock Rises 16% in a Week: Here's What You Should Know (Zacks)
10:11AM	AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week? (Zacks)
08:50AM	AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy (Benzinga)
08:32AM	How J&J's Innovative Medicines Segment is Poised Ahead of Q3 Results (Zacks)
07:00AM	DATROWAY (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02 (Business Wire)
Oct-03-25 06:15PM	Astrazeneca (AZN) Rises Higher Than Market: Key Facts (Zacks)
04:16PM	How BeOne Medicines, An IBD 50 Stock, Is Taking On Big Names In Cancer Treatment (Investor's Business Daily)
10:06AM	MRK Stock Up Nearly 14% So Far This Week: What's Driving It? (Zacks)
09:59AM	Is PFE Stock a Buy After 14% Rise Post Drug Pricing Deal With Trump? (Zacks)
Oct-02-25 12:22PM	AstraZeneca Stock Is Up 10% on Tariff News. But Is the Pharmaceutical Giant a Buy? (Motley Fool)
09:50AM	Why Astrazeneca (AZN) is a Top Momentum Stock for the Long-Term (Zacks)
03:48AM	AstraZeneca (AZN) Jumps to All-Time High on Trump Drug Tariff Delay (Insider Monkey)
Oct-01-25 04:36PM	Why Drug Stocks Are Celebrating Trump's 100% Pharmaceutical Tariff (Investor's Business Daily) +9.96%
10:54AM	AstraZeneca shares leap with FDA set to review drug to treat breast cancer (MarketWatch)
07:52AM	Stocks to Watch Wednesday: Nike, Lithium Americas, Cal-Maine, Occidental (The Wall Street Journal)
Sep-30-25 09:40AM	Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year? (Zacks)
06:30AM	Genmab Strikes $8 Billion Deal for Cancer Treatment Maker Merus (The Daily Upside)
Sep-29-25 04:25PM	GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley (Investor's Business Daily)
08:25AM	AstraZeneca Moves From ADRs To NYSE Listing (Benzinga)
08:07AM	CoreWeave, AstraZeneca, GSK, BYD, Tesla: Trending Stocks (Yahoo Finance Video)
07:37AM	GSK CEO Emma Walmsley to Step Down as Commercial Chief Takes Helm (The Wall Street Journal)
07:37AM	AstraZeneca to List Shares Directly on New York Stock Exchange (The Wall Street Journal)
07:00AM	ENHERTU (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial (Business Wire)
06:59AM	Stocks to Watch Monday: Carnival, GSK, Alibaba (The Wall Street Journal)
04:06AM	AstraZeneca to list directly on NYSE while keeping U.K. listing; shares up (Investing.com)
Sep-27-25 06:45AM	3 Magnificent Stocks Under $100 to Buy Right Now (Motley Fool)
12:59AM	AstraZeneca (AZN) Stock Target Raised as Goldman Sachs Sees $3.7 Billion Drug Potential (Insider Monkey)
Sep-26-25 05:50PM	Trumps Latest Tariffs Raise More Questions. Investors Need to Stay Alert. (Barrons.com)
01:34PM	Your AstraZeneca Medicine Could Be Cheaper As Much As 70% (Benzinga)
11:43AM	AstraZeneca to Offer Discounted Drugs As Trump Pressures Pharma Industry to Cut Prices (The Wall Street Journal)
11:10AM	Analysts Cite Amgen's (AMGN) Strong Therapies Pipeline to Reaffirm Bullish Outlook (Insider Monkey)
09:24AM	Trump Slams 100% Tariff on Imported Drugs: Pharma ETFs Take a Hit (Zacks)
09:00AM	AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions (Business Wire)
06:58AM	Stock Futures Waver After Trump Unveils New Tariffs (The Wall Street Journal)
05:31AM	Stock Market Today: Dow, S&P 500 and Nasdaq futures inch higher after three days of losses for stocks, with Fed's preferred inflation gauge ahead and fresh tariff announcements from Trump (MarketWatch)
05:30AM	U.S. stock futures indicate a losing streak could be over as PCE inflation looms and after fresh tariffs announced (MarketWatch)
03:41AM	European Pharmaceutical Stocks Fall On New Trump Tariffs (The Wall Street Journal)
03:17AM	Trump Plans New Tariff Push With 100% Rate on Patented Drugs (Bloomberg)
Sep-25-25 06:15PM	Astrazeneca (AZN) Declines More Than Market: Some Information for Investors (Zacks)
12:53PM	Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment? (Zacks)
11:52AM	AstraZeneca Stock Rises 15% YTD: Should You Buy, Sell or Hold? (Zacks)
11:20AM	AZN, Daiichi's Enhertu sBLA Gets FDA Priority Review for Breast Cancer (Zacks)
09:45AM	Here's Why Astrazeneca (AZN) is a Strong Growth Stock (Zacks)
Sep-24-25 09:40AM	Here's Why Astrazeneca (AZN) is a Strong Value Stock (Zacks)
02:30AM	Why One Top International Fund Likes Novo Nordisk Stock (Barrons.com)
Sep-23-25 02:15PM	IONS' Rare Neurological Disease Drug Meets Late-Stage Study Goal (Zacks)
11:57AM	AZN Gets CHMP Nod for Label Expansion of Koselugo & Tezspire (Zacks)
Sep-22-25 08:00AM	SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer (PR Newswire)
Sep-21-25 05:30AM	How the FDA Is Taking Aim at the Surreal World of TV Drug Ads (The Wall Street Journal)

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company's history roots back to the year 1913 when Astra business was formed. AstraZeneca was founded in 1999 through the merger of Astra AB and Zeneca Group PLC. The company is headquartered in Cambridge, the United Kingdom.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AZN

Astrazeneca plc ADR

Upgrade your FINVIZ experience